Cargando…
The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
BACKGROUND: Despite emerging treatments for hereditary transthyretin (ATTRv) amyloidosis, the disease is often misdiagnosed, with reported diagnostic delays of up to several years. Knowledge of the patient journey leading up to diagnosis may help to promote earlier intervention. The study’s objectiv...
Autores principales: | Vera-Llonch, Montserrat, Reddy, Sheila R., Chang, Eunice, Tarbox, Marian H., Pollock, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798313/ https://www.ncbi.nlm.nih.gov/pubmed/33430941 http://dx.doi.org/10.1186/s13023-020-01623-1 |
Ejemplares similares
-
The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
por: Reddy, Sheila R., et al.
Publicado: (2020) -
Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
por: Magliano, Lorenza, et al.
Publicado: (2021) -
Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2022) -
Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy
por: Dardiotis, Efthimios, et al.
Publicado: (2023) -
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)